DEBIRI and cetuximab (DEBIRITUX) as a secondline treatment for unresectable colorectal liver metastases (UCLM): results of a phase II trial exploring a new sequence

Aim: To investigate efficacy and safety of second-line treatment with Irinotecan-loaded Drug-eluting Beads (DEBIRI ) and cetuximab of unresectable colorectal liver metastases. Methods: Patients with the following characteristics were included in the study: unresectable hepatic metastases from colorectal carcinoma (CRC), progression after first line chemotherapy (any type of chemotherapeutic drug and combination was allowed), second line...